235 related articles for article (PubMed ID: 33829343)
1. Cardiac hERG K
Su S; Sun J; Wang Y; Xu Y
Handb Exp Pharmacol; 2021; 267():139-166. PubMed ID: 33829343
[TBL] [Abstract][Full Text] [Related]
2. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
3. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
4. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
5. The hERG channel activator, RPR260243, enhances protective
Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136
[TBL] [Abstract][Full Text] [Related]
6. The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT.
Mechakra A; Vincent Y; Chevalier P; Millat G; Ficker E; Jastrzebski M; Poulin H; Pouliot V; Chahine M; Christé G
Gene; 2014 Feb; 536(2):348-56. PubMed ID: 24334129
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
Furutani K
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
[TBL] [Abstract][Full Text] [Related]
8. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation.
Aromolaran AS; Srivastava U; Alí A; Chahine M; Lazaro D; El-Sherif N; Capecchi PL; Laghi-Pasini F; Lazzerini PE; Boutjdir M
PLoS One; 2018; 13(12):e0208321. PubMed ID: 30521586
[TBL] [Abstract][Full Text] [Related]
10. HERG trafficking and pharmacological rescue of LQTS-2 mutant channels.
Robertson GA; January CT
Handb Exp Pharmacol; 2006; (171):349-55. PubMed ID: 16610352
[TBL] [Abstract][Full Text] [Related]
11. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
12. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
13. The hERG potassium channel as a therapeutic target.
Witchel HJ
Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
[TBL] [Abstract][Full Text] [Related]
14. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HERG potassium channel function by drug action.
Thomas D; Karle CA; Kiehn J
Ann Med; 2004; 36 Suppl 1():41-6. PubMed ID: 15176423
[TBL] [Abstract][Full Text] [Related]
18. The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review.
Gelman I; Sharma N; Mckeeman O; Lee P; Campagna N; Tomei N; Baranchuk A; Zhang S; El-Diasty M
Biomed Pharmacother; 2024 May; 174():116513. PubMed ID: 38565056
[TBL] [Abstract][Full Text] [Related]
19. Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization.
Cheng JH; Kodama I
Acta Pharmacol Sin; 2004 Feb; 25(2):137-45. PubMed ID: 14769199
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].
Chachin M; Kurachi Y
Nihon Yakurigaku Zasshi; 2002 Jun; 119(6):345-51. PubMed ID: 12089906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
